Core Viewpoint - MannKind Corporation is focused on creating shareholder value, minimizing dilution, and enhancing flexibility as it enters the next phase of growth, with expectations for significant developments over the next 6 to 8 quarters [5]. Group 1: Company Overview - MannKind Corporation held its Q2 2025 earnings call on August 6, 2025, featuring key participants including CEO Michael Castagna and CFO Christopher Prentiss [1][2][3]. - The company aims to showcase the cumulative work of the past 7 years in the upcoming quarters [5]. Group 2: Financial Performance - The earnings call is part of the company's efforts to communicate its financial results and future outlook to stakeholders [2][3].

Group 1 - The article highlights MannKind Corporation (NASDAQ: MNKD) as a focus for investment discussions, particularly in the context of its recent second-quarter results [1] - The Biotech Forum, led by Bret, offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [1] - The forum has seen increased interest in covered call opportunities among biotech investors in recent quarters [1] Group 2 - The article does not provide any specific financial metrics or performance data for MannKind Corporation in the second quarter [1]

For the quarter ended June 2025, MannKind (MNKD) reported revenue of $76.53 million, up 5.7% over the same period last year. EPS came in at $0, compared to $0.05 in the year-ago quarter.The reported revenue represents a surprise of -2.58% over the Zacks Consensus Estimate of $78.55 million. With the consensus EPS estimate being $0.04, the EPS surprise was -100%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations ...

Financial Data and Key Metrics Changes - The company reported Q2 revenues of $77 million, a 6% increase over 2024, and year-to-date revenues of $155 million, reflecting a 12% increase over 2024 [6][18] - The balance sheet remains strong with $201 million in cash and access to $500 million in non-dilutive capital from Blackstone [7][22] - Total revenues over the trailing four quarters exceeded $300 million, with expectations for continued growth [18] Business Line Data and Key Metrics Changes - The endocrine business unit generated $18.3 million in revenue, representing a 13% growth over 2024 [6] - Afrezza net revenues for Q2 were $18 million, a 13% increase year-over-year, while V Go net revenue was approximately $4 million, an 8% decrease [19][20] - Tyvaso DPI royalties contributed $31 million in Q2, marking a 22% increase from the same quarter last year [18] Market Data and Key Metrics Changes - The company targets about 25% of all rapid-acting scripts, with 1% of the rapid-acting market estimated at a $300 million run rate for Afrezza [4] - The NTM market is expected to exceed $1 billion by the end of the decade, with a focus on the US and Japan [7] Company Strategy and Development Direction - The company is focused on creating shareholder value, minimizing dilution, and enhancing flexibility for future growth [3] - Upcoming trials include the launch of the inflow trial for NTM by the end of 2025 and the pediatric indications for Afrezza [6][14] - The company aims to enhance its commercial infrastructure and expand its sales force in preparation for the pediatric launch of Afrezza [16][73] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming TETON-two results and their potential impact on business plans [3][14] - The company anticipates continued growth in royalty revenue driven by Tyvaso DPI sales and expects Afrezza to maintain its growth trajectory [20][21] - Management highlighted the importance of the Blackstone deal in providing the necessary capital for growth and innovation [25][22] Other Important Information - The company has entered into a strategic financing arrangement with Blackstone, providing access to up to $500 million in non-dilutive funding [22] - The company is preparing for a new marketing campaign called "insulin in the moment" to enhance awareness and adoption of Afrezza [15] Q&A Session Summary Question: Can you walk us through the timeline for a potential bridging study in IPF? - Management indicated that the timeline could be faster than previous studies, depending on the results of TETON-two and TETON-one [30][31] Question: How is the intended DPI program positioned in the current treatment landscape? - Management noted that the program is designed to be used in combination with existing therapies and is focused on patients intolerant to current treatments [34][40] Question: What is the typical Afrezza patient profile today? - The breakdown of patients is approximately 45% Type 1 and 55% Type 2, with a growing focus on Type 1 patients [66][67] Question: What are the conditions for drawing additional capital from the Blackstone agreement? - The company can draw funds at its discretion without specific sales or development milestones [98]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 13-3607736 (State or other jurisdiction of inc ...

Conference call today at 9:00 am ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif. August 6, 2025 (Globe Newswire) — MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter 2025 and provided a business update. "The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "In our o ...

Core Viewpoint - MannKind Corporation has entered into a strategic financing agreement with Blackstone, providing up to $500 million in non-dilutive capital to support its growth strategies and commercial initiatives [1][2]. Group 1: Financing Details - MannKind will receive an initial $75 million in cash at closing, with a total financing facility of up to $500 million [1]. - The financing includes a $125 million delayed draw term loan (DDTL) available over the next 24 months, and an additional $300 million uncommitted DDTL subject to mutual consent [2]. - The facility bears interest at a SOFR variable rate plus 4.75%, with potential increases based on leverage ratios, and matures in August 2030 without scheduled amortization payments [2]. Group 2: Strategic Implications - The funding will enhance MannKind's operational flexibility and support the expansion of its commercial team in anticipation of the pediatric indication for Afrezza, pending approval [2]. - The capital will also facilitate continued pipeline advancement and potential business development opportunities [2]. - Blackstone's involvement is expected to provide MannKind with access to a value creation platform and life sciences expertise, aiding in commercialization efforts [2]. Group 3: Company Overview - MannKind Corporation focuses on developing and commercializing inhaled therapeutic products for endocrine and orphan lung diseases [3]. - The company aims to address serious unmet medical needs through innovative dry-powder formulations and inhalation devices [4].

Core Insights - MannKind Corporation reported a 6% increase in revenues for Q2 2025, totaling $76.5 million compared to $72.4 million in Q2 2024, driven by higher sales of Afrezza and royalties from Tyvaso DPI [6][9] - The company submitted a supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients, marking a significant milestone [2][7] - MannKind is advancing its orphan lung pipeline, with the ICoN-1 trial for inhaled clofazimine ahead of schedule and plans to initiate a Phase 2 trial for nintedanib DPI by the end of 2025 [4][5] Financial Performance - Year-to-date revenues for 2025 reached $154.9 million, a 12% increase from $138.6 million in the same period of 2024 [11][13] - Afrezza sales in Q2 2025 were $18.3 million, up 13% from $16.3 million in Q2 2024 [8][9] - The company reported a net income of $0.7 million for Q2 2025, compared to a net loss of $2.0 million in Q2 2024, reflecting a $2.7 million improvement [12][24] Research and Development - Research and development expenses increased by 16% in Q2 2025, primarily due to ongoing patient enrollment in the ICoN-1 study and increased personnel costs [12][20] - The company plans to initiate a Phase 2 clinical trial for nintedanib DPI for idiopathic pulmonary fibrosis (IPF) by the end of 2025 [5][20] Market Position and Strategy - MannKind's majority of revenue and future pipeline programs are derived from its U.S.-based manufacturing facility in Danbury, CT, which mitigates potential tariff exposure [8] - The company is focused on developing innovative inhaled therapeutic products to address unmet medical needs in diabetes and orphan lung diseases [16][17]

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its second quarter 2025 financial results will be released before market open on August 6, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be ...

Core Insights - MannKind Corporation will showcase its inhaled insulin product, Afrezza, at the American Diabetes Association's 85th Scientific Sessions from June 20-23, 2025, in Chicago [1][5] - Dr. Michael J. Haller will present results from the INHALE-1 clinical trial, focusing on inhaled insulin treatment for children and adolescents aged 4-17 [2][3] - MannKind plans to submit a Supplemental Biologics License Application for a pediatric indication for Afrezza in mid-2025, following the release of topline results from the full pediatric data set in Q2 2025 [5] Company Overview - MannKind Corporation specializes in developing and commercializing inhaled therapeutic products and delivery devices for endocrine and orphan lung diseases [6][7] - The company aims to address serious unmet medical needs through innovative dry-powder formulations and inhalation devices, providing rapid and convenient delivery of medications [7] Upcoming Events - The ADA's Scientific Sessions will feature a symposium titled "Future Ready," where breakthrough advancements in pediatric Type 1 diabetes care will be discussed [3] - MannKind will host a booth (1617) at the event for scientific exchange and to showcase its products [4]